Reply
Reply
First published: 26 November 2008
No abstract is available for this article.
- 1
Kavey RE,
Allada V,
Daniels SR,
Hayman LL,
McCrindle BW,
Newburger JW, et al.
Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics [review].
Circulation
2006;
114:
2710–38.
- 2
Do Prado R,
D'Almeida VM,
Guerra-Shinohara E,
Galdieri LC,
Terreri MT,
Hilario MO.
Increased concentration of plasma homocysteine in children with systemic lupus erythematosus.
Clin Exp Rheumatol
2006;
24:
594–8.
- 3
Petri M,
Roubenoff R,
Dallal GE,
Nadeau MR,
Selhub J,
Rosenberg IH.
Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus.
Lancet
1996;
348:
1120–4.
- 4
Von Feldt JM,
Scalzi LV,
Cucchiara AJ,
Morthala S,
Kealey C,
Flagg SD, et al.
Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus.
Arthritis Rheum
2006;
54:
2220–7.
- 5
Wahl DG,
Bounameaux H,
de Moerloose P,
Sarasin FP.
Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis.
Arch Intern Med
2000;
160:
2042–8.
- 6
Schanberg LE,
Sandborg C.
Dyslipoproteinemia and premature atherosclerosis in pediatric systemic lupus erythematosus.
Curr Rheumatol Rep
2004;
6:
425–33.
